Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. on March 23, 2016. The filing serves to announce the company's financial results for the fourth quarter and the full year ended December 31, 2015. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1), which is not part of the provided text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that results for the fourth quarter and year ended December 31, 2015, were announced.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated. The company explicitly states it does not assume any obligation to update the information in the future. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release dated March 23, 2016) for actual financial figures, as they are absent from the 8-K body text.
- Verify the specific revenue and net loss figures for Q4 and full-year 2015.
- Check the company's cash position and burn rate to assess liquidity runway.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the full press release.